HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble

A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, casting a shadow over the company’s momentum as the star PD-1xVEGF bispecific heads into the ASCO annual meeting with a prestigious spot on the plenary session.

By FiercePharma · May 3, 2026 · via FiercePharma
Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
pipelineformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
PipelineFierceBiotech ↗
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestran…
May 2, 2026
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
PipelineBriefing
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
FDA authorizes Auvelity for agitation tied to Alzheimer’s disease, positioning Axsome’s NMDA/sigma-1 modulator…
May 2, 2026
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
PipelineBioPharma Dive ↗
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still…
May 1, 2026